METTL3 and hepatocellular carcinoma: Through m6A modification, METTL3 upregulates autophagy‐related LC3, ATG5, and ATG7 expression which contribute to resistance development to gefitinib.[69] In contrast, METTL3 downregulation promotes sorafenib resistance and activates autophagic pathways in hepatocellular carcinoma.